DaVita Inc.
corporate_fare Company Profile
DaVita Inc. (NYSE:DVA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for DVA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for DVA spans 10-Q, 8-K, 4, 144.
Recent high-impact activity:
- Washington State Sues DaVita, Fresenius Over Nephrologist Noncompetes
- DaVita 10-Q Details Q3 EPS of $3.40, $62M China Impairment and $862M of Buybacks
- DaVita Q3 EPS $3.40, Adjusted $3.82; 2026 EPS Guidance Narrowed to $14.30-$15.20
- DaVita Posts 3Q Adjusted EPS of $3.82
- DaVita Wins Preliminary Approval for Ransomware Class Action Settlement
Financial Snapshot
Short Interest & Short Volume
5.14 days to coverFINRA reported short interest of 5,141,769 shares in DVA as of the October 30, 2026 settlement, a 4.8% increase from the prior period — about 5.1 days to cover at its recent average daily volume. On November 20, 2026, 65.5% of DVA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.